TrialBreast cancer research : BCR2024

TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.

Filipa Lynce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.